163 related articles for article (PubMed ID: 35179064)
61. Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use.
Hughes ME; Landsburg DJ; Rubin DJ; Schuster SJ; Svoboda J; Gerson JN; Namoglu E; Nasta SD
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):791-798. PubMed ID: 31648953
[TBL] [Abstract][Full Text] [Related]
62. Venetoclax alone or in combination with other regimens treatment achieve deep and sustained remission of relapsed/refractory chronic lymphocytic leukemia: a meta-analysis.
Tang X; Zou W; Peng P; Bai Y
Clin Exp Med; 2022 May; 22(2):161-171. PubMed ID: 34224006
[TBL] [Abstract][Full Text] [Related]
63. Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts.
Barr PM; Tedeschi A; Wierda WG; Allan JN; Ghia P; Vallisa D; Jacobs R; O'Brien S; Grigg AP; Walker P; Zhou C; Ninomoto J; Krigsfeld G; Tam CS
Clin Cancer Res; 2022 Oct; 28(20):4385-4391. PubMed ID: 35939599
[TBL] [Abstract][Full Text] [Related]
64. Monitoring of blood levels in patients administered CYP3A4 inhibitor during the maintenance phase of venetoclax administration
.
Kubo T; Matsuo S; Sogawa R; Yasu T; Nagaie T; Okamoto S; Kimura S; Shimanoe C
Int J Clin Pharmacol Ther; 2024 Jan; 62(1):56-60. PubMed ID: 37969095
[TBL] [Abstract][Full Text] [Related]
65. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA
Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251
[TBL] [Abstract][Full Text] [Related]
66. Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
Shadman M; Manzoor BS; Sail K; Tuncer HH; Allan JN; Ujjani C; Emechebe N; Kamalakar R; Coombs CC; Leslie L; Barr PM; Brown JR; Eyre TA; Rampotas A; Schuh A; Lamanna N; Skarbnik A; Roeker LE; Bannerji R; Eichhorst B; Fleury I; Davids MS; Alhasani H; Jiang D; Hill BT; Schuster SJ; Brander DM; Pivneva I; Burne R; Guerin A; Mato AR
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):515-526. PubMed ID: 37076367
[TBL] [Abstract][Full Text] [Related]
67. Concomitant Venetoclax and Imatinib for Comanaging Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia: A Case Report.
Przespolewski ER; Baron J; Kashef F; Fu K; Jani Sait SN; Hernandez-Ilizaliturri F; Thompson J
J Natl Compr Canc Netw; 2023 Feb; 21(2):102-107. PubMed ID: 36791756
[TBL] [Abstract][Full Text] [Related]
68. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.
Roberts AW; Stilgenbauer S; Seymour JF; Huang DCS
Clin Cancer Res; 2017 Aug; 23(16):4527-4533. PubMed ID: 28100580
[TBL] [Abstract][Full Text] [Related]
69. Lessons learned from the CAPTIVATE trial of ibrutinib plus venetoclax in CLL.
O'Brien SM
Clin Adv Hematol Oncol; 2021 Oct; 19(10):636-638. PubMed ID: 34637429
[No Abstract] [Full Text] [Related]
70. Anaemia during venetoclax ramp-up phase: Do not forget unusual causes.
Cavarretta CA; Visentin A; Pravato S; Piva E; Piazza F; Basso D; Trentin L
Int J Lab Hematol; 2022 Oct; 44(5):e211-e214. PubMed ID: 35538897
[No Abstract] [Full Text] [Related]
71. Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients.
Ferrarini I; Gandini F; Zapparoli E; Rigo A
Curr Oncol; 2022 Apr; 29(4):2792-2797. PubMed ID: 35448201
[TBL] [Abstract][Full Text] [Related]
72. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
Fischer K; Al-Sawaf O; Bahlo J; Fink AM; Tandon M; Dixon M; Robrecht S; Warburton S; Humphrey K; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Boettcher S; Tausch E; Humerickhouse R; Eichhorst B; Wendtner CM; Langerak AW; Kreuzer KA; Ritgen M; Goede V; Stilgenbauer S; Mobasher M; Hallek M
N Engl J Med; 2019 Jun; 380(23):2225-2236. PubMed ID: 31166681
[TBL] [Abstract][Full Text] [Related]
73. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
Cramer P; von Tresckow J; Bahlo J; Robrecht S; Langerbeins P; Al-Sawaf O; Engelke A; Fink AM; Fischer K; Tausch E; Seiler T; Fischer von Weikersthal L; Hebart H; Kreuzer KA; Böttcher S; Ritgen M; Kneba M; Wendtner CM; Stilgenbauer S; Eichhorst B; Hallek M
Lancet Oncol; 2018 Sep; 19(9):1215-1228. PubMed ID: 30115596
[TBL] [Abstract][Full Text] [Related]
74. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP
N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156
[TBL] [Abstract][Full Text] [Related]
75. Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.
Vitale C; Salvetti C; Griggio V; Porrazzo M; Schiattone L; Zamprogna G; Visentin A; Vassallo F; Cassin R; Rigolin GM; Murru R; Laurenti L; Rivela P; Marchetti M; Pennese E; Gentile M; Boccellato E; Perutelli F; Montalbano MC; De Paoli L; Reda G; Orsucci L; Trentin L; Cuneo A; Tedeschi A; Scarfò L; Gaidano G; Mauro FR; Foà R; Boccadoro M; Coscia M
Blood; 2021 Jun; 137(25):3507-3517. PubMed ID: 33651883
[TBL] [Abstract][Full Text] [Related]
76. Venetoclax in the treatment of chronic lymphocytic leukemia.
Korycka-Wolowiec A; Wolowiec D; Kubiak-Mlonka A; Robak T
Expert Opin Drug Metab Toxicol; 2019 May; 15(5):353-366. PubMed ID: 30969139
[TBL] [Abstract][Full Text] [Related]
77. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.
Cramer P; Fürstenau M; Robrecht S; Giza A; Zhang C; Fink AM; Fischer K; Langerbeins P; Al-Sawaf O; Tausch E; Schneider C; Schetelig J; Dreger P; Böttcher S; Kreuzer KA; Schilhabel A; Ritgen M; Brüggemann M; Kneba M; Stilgenbauer S; Eichhorst B; Hallek M
Lancet Haematol; 2022 Oct; 9(10):e745-e755. PubMed ID: 35988545
[TBL] [Abstract][Full Text] [Related]
78. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
Anderson MA; Tam C; Lew TE; Juneja S; Juneja M; Westerman D; Wall M; Lade S; Gorelik A; Huang DCS; Seymour JF; Roberts AW
Blood; 2017 Jun; 129(25):3362-3370. PubMed ID: 28473407
[TBL] [Abstract][Full Text] [Related]
79. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.
Freise KJ; Dunbar M; Jones AK; Hoffman D; Enschede SL; Wong S; Salem AH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):847-53. PubMed ID: 27586967
[TBL] [Abstract][Full Text] [Related]
80. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Freise KJ; Jones AK; Menon RM; Verdugo ME; Humerickhouse RA; Awni WM; Salem AH
Hematol Oncol; 2017 Dec; 35(4):679-684. PubMed ID: 27982454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
